We show that treatment of adult mice with recombinant human insulin-like growth factor 1 (rhIGF-1) induces striking modifications in lymphocyte number and function. 9-mo-old male mice received rhIGF-1 (4 mg/kg per d) or its excipient by subcutaneous infusion from osmotic minipumps for 7 or 14 d. Mice were weighed daily and bled at sacrifice; the spleen and thymus were harvested and single cell suspensions were made for analysis of cell phenotype and cell number. The responses of splenocytes to mitogens (concanavalin A, lipopolysaccharide, and pokeweed mitogen), alloantigens and dinitrophenyl ovalbumin were measured. After either 7 or 14 d of treatment, rhIGF-1 had an overall whole-body anabolic effect, resulting in increased body and organ weights with prominent increases in the weight of the spleen and thymus. Furthermore, the rhIGF-1 treated mice were normoglycemic but had reduced blood urea nitrogens, again reflecting the anabolic activity of rhIGF-1. The increased spleen and thymus weights were associated with a large increase in the number of lymphocytes in both organs. In addition to an increase in T cells, specifically CD4 + T cells, a dramatic increase in splenic B cells was also observed. This increase was accompanied by an enhanced responsiveness to dinitrophenyl ovalbumin resulting in increased immunoglobulin production. However, despite the increases in cellularity, there was a decrease in the in vitro responses of spleen cells to mitogens after 7 d of rhIGF-1 treatment. In contrast, treatment with rhIGF-1 for 14 d increased both the cell number and mitogenic responses of splenocytes suggesting that some time is required for the cells populating the peripheral organs to gain mitogenic responsiveness. It is clear from these data that rhIGF-1, at doses that have whole-body anabolic activity, can expand cell number in lymphoid tissue in a normal adult mouse. These dual effects of rhIGF-1, of increasing lymphocyte number and activity, indicate that, in a normal adult animal, rhIGF-1 can cause major changes in lymphoid tissues that are of potential benefit to the functioning of the immune system. (J.
Insulin-like growth factor-I (IGF-l ), ' a 70-amino acid peptide structurally related to insulin, is normally considered to be a metabolic hormone which mediates many of the anabolic effects ofgrowth hormone (GH) ( 1 ) . These anabolic activities of IGF-1 were initially quantitated in GH-deficient or hypophysectomized rats, and a common finding has been that recombinant human IGF-1 (rhIGF-1 ) increases spleen and thymus weight disproportionately to its effect on whole-body size (1) (2) (3) (4) . However, direct comparisons of the anabolic activities of GH and IGF-1 suggest that they have differential effects on organ growth. For example, GH has a large effect on epiphyseal cartilage growth while IGF-1 has a greater effect on splenic weight (3) .
In addition to these established anabolic effects, there is a growing body of evidence that links growth hormone to the immune system (5-7). For example, mice with hereditary GH deficiency develop an impaired immune system associated with thymic atrophy, immunodeficiency, and tissue wasting which is believed to contribute to the shortened life expectancy of these mice (8) . Conversely, administration of exogenous GH induces T-cell proliferation in the thymus (9, 10) and can alter the activity of all major immune cell types, including T cells, B cells, natural killer (NK) cells, and macrophages ( 11 ) . It has been hypothesized that long-term, low-dose GH therapy increases immune function and life expectancy ofaged BALB/c mice ( 12) .
There are fewer reports on the direct effects of IGF-1 on immune parameters despite the possibility that the actions of GH on lymphocytes may be mediated by the local induction of IGF-1, which then acts through the type-l IGF receptor ( 13) . Indeed, recent data suggest that B cells and activated T cells possess receptors for IGF-1 (14, 15) . Further, at nanomolar concentrations, IGF-1 has been shown in vitro to be a growthpromoting factor for lymphocytes and to be chemotactic for resting and activated T cells ( 16) .
In addition to these effects on lymphocytes, IGF-1 has been reported to enhance the maturation of morphologically recognizable granulocytic and erythroid progenitors in suspension cultures of marrow cells ( 17) . In vivo, infusions of rhIGF-l increase thymus and spleen weight in hypophysectomized rats ( 1, 2) and dwarf rats (3) , and induce repopulation ofthe atrophied thymus in diabetic rats (4) . In addition, there is a report in the rat that rhIGF-1 can enhance thymic recovery after cyclosporine treatment ( 18) . These reports suggest that IGF-1 may have endocrine, paracrine, or autocrine effects on the immune system.
The effects on lymphoid tissue after in vivo administration ofrhIGF- 1 have been described only in gross anatomical terms as an increased weight of spleen or thymus (1) (2) (3) (4) , whereas the studies in vitro have focused primarily on the effects on T cells. There are few data describing the effects of in vivo administration of rhIGF-1 on the number, phenotype, or responsiveness of lymphocytes. We now show that short-term administration of rhIGF-1 to normal adult retired breeder mice has profound effects on lymphoid tissues owing to increases predominately in CD4' T cells and, quite unexpectedly, B cell populations resulting in enhanced immunoglobulin synthesis. Interestingly, there is an associated but delayed increase in T and B cell responsiveness to mitogens after rhIGF-1 administration.
Methods
Animals. Male retired breeder BALB/c mice 9 mo old, weighing [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] g (obtained from Harlan Sprague Dawley, San Diego, CA), were housed in single cages in a light-and temperature-controlled room. Food (Rodent Chow 5010, Ralston Purina Co., St. Louis, MO) and water were given ad libitum, and the mice were identified with ear tags and acclimated for at least 1 wk before treatment. The mice were then weighed and randomized into treatment groups to give groups ofequal initial body weight.
Experimental design. Three independent studies, designated studies A, B, and C, were carried out to assess the effects of rhIGF-1 on immune parameters. In each study rhIGF-1 was given by subcutaneous (sc) infusion for either 7 (studies A and B) or 14 d (study C). In study A, three doses of rhIGF-1 were used to establish an effective anabolic dose of rhIGF-I in normal mice. In study A, rhIGF-I was given for 7 filled, using sterile techniques, with rhIGF-l or the excipient buffer, then preincubated overnight in saline to reduce the likelihood of an initial burst ofrhIGF-I release from the pump. The animals were anesthetized with an intraperitoneal (i.p.) injection of 0.4 ml of avertin (6 ,ug of 2,2,2-tribromethanol in PBS). An incision was made in the dorsal scapular region and either one or two minipumps inserted caudally into the sc pocket and the incision closed with metal wound clips. An injection of penicillin (7,500 U, s.c.) was then given and the animals were replaced in their individual cages. The mice were weighed and inspected daily. Cell preparation. 7 or 14 d after the pumps were implanted, mice were bled by orbital puncture and killed by cervical dislocation, and the heart, liver, and kidneys were removed and weighed. The spleen and the thymus were removed, weighed, and placed in tissue culture medium on ice. The spleen and thymus were then individually dispersed between sintered glass slides to form single-cell suspensions. For use in the in vitro assays the cells were washed in Eagle's MEM (Gibco, Grand Island, NY), containing 10% FBS (Gibco), penicillin (100 U/ml), 100 sg/ml streptomycin (Gibco), and 200 mM glutamine), and resuspended at In vitro immunoglobulin synthesis. 2 wk after pump implantation, spleens were removed, single-cell suspensions were made, and splenocytes were stimulated for IgG synthesis. Splenocytes (2 X I05 cells/ml) were incubated in 200 Al of MEM. DNP20A (10 g/ml) was added at the initiation ofculture. Cultures were incubated in 5% CO2 at 370C for 96 h. Supernantants were harvested and the total IgG antibody concentration was measured using the ELISA format described.
Measurement of IgG antibodies: total IgG. IgG antibodies in the culture supernatants were measured by an ELISA using 96-well plates and murine IgG as a reference standard. Each well was coated with 0.1 ml of 1:200 goat anti-murine IgG-Fc specific antibody (Cappel Laboratories, Westchester, PA) for 24 h at 4VC. After blocking with 0.1% BSA, 0.1 ml of culture supernatant was added in triplicate to the coated plates. After a 2-h incubation at room temperature, the plates were washed three times with PBS/0.02% Tween 20, and 0.1 ml ofa 1:5,000 dilution of horseradish peroxidase conjugated-Fab specific goat antimouse IgG (Boehringer Mannheim Biochemicals, Indianapolis, IN) was added. The plates were incubated for an additional 2 h and washed, and 0.1 ml of0.2 mg/ml o-phenylenediamine, 0.01% H202 in PBS was added to each well, the reaction was stopped with 2 M H2SO4 after 30 min, and the OD was read at 490 nm on a plate reader (Molecular Devices Corp., Menlo Park, CA). MA) and harvested 6 h later onto glass fiber filters using a multiple sample harvester. Discs were dried and placed in 3 ml of scintillation fluid, [3H]thymidine incorporation into DNA was measured using a scintillation counter (LS 1701, Beckman Instruments, Inc., Palo Alto, CA), and triplicate determinations were averaged. Mitogen responses are expressed as the stimulation index (SI), which is the ratio of the radioactivity (cpm) at the maximally stimulated concentration divided by the cpm in control nonmitogen-stimulated cultures.
Mixed lymphocyte reactions. One-way murine mixed lymphocyte cultures were established in 96-well flat-bottomed microtiter plates according to the method of Ranges et al. (19) . Briefly, 1.5 X 105 responder splenocytes from either excipient or rhIGF-1-treated mice were cocultured with an equal number of allogeneic irradiated Phenotypic analysis oflymphoid populations. Lymphocyte cell suspensions, prepared as described above, were adjusted to 1 X 106 cells/ ml in PBS containing 0.1% BSA and 10 mM sodium azide. To stain the T cell populations, the cell suspensions (200 Ml) were incubated for 30 min at 4°C with 5gl of the appropriate dilution ofFITC-conjugated rat anti-mouse Thy-1, L3T4, Lyt-2, (Caltag, S. San Francisco, CA) or FITC-conjugated peanut agglutinin (PNA) (Sigma Chemical Co.). The B cells were stained using FITC-conjugated F(ab')2 polyclonal goat anti-mouse Ig (IgM, IgG, IgA specific) (Cappell-Organon Tek- Statistical significance is indicated as: * P < 0.05, * P < 0.01, § P < 0.001 vs. excipient treated mice.
nika, West Chester, PA). After three washes with cold medium, cells were analyzed for degree of fluorescence intensity using a FACScan (Becton Dickinson & Co., Sunnyvale, CA). Fluorescence parameters were collected using a log amplifier after gating on the combination of forward and perpendicular light scatter. Fluorescence data was expressed as percentage of fluorescent cells compared to a nonrelevant mAb of an identical isotype. Fluorescence was measured as mean intensity of the cells expressed as mean channel number plotted on a log scale.
Blood analyses. Blood glucose (coupled hexokinase procedure), cholesterol, globulin, total protein, blood urea nitrogen, and creatinine were measured in the sera using a Monarch 2000 Chemical Systems instrument (Allied Instrument Laboratories, Lexington, MA). Total serum IGF-1 was measured after acid-ethanol extraction by radioimmunoassay, using rhIGF-l (M3-RD1, Genentech, Inc., S. San Francisco, CA) as the standard and rabbit anti-IGF-l antiserum kindly supplied by Dr. P. Gluckman (University ofAuckland, New Zealand). The acceptable range was 1.25-40 ng/ml, while intra-and interassay variability were 5-9% and 6-15%, respectively.
Statistical analysis. Statistically significant differences between treatment groups were established by analysis of variance, and for study A 
Results
Anabolic effects. Table I shows the body and organ weights after treatment with the various doses of rhIGF-1. Because the control mice were > 9 mo ofage, and therefore in growth stasis, only small weight gains were observed in the control mice during the treatment interval. However, it is clear that rhIGF-l produced a dose related anabolic response. In all three of the studies, there was a highly consistent increase in body weight gain in the rhIGF-1-treated mice compared with excipienttreated controls. In study A there was a dose-related effect of rhIGF-l on body weight gain over the 7 d (excipient 0.75±0.75 g, low dose 0.86±0.63 g, medium dose 1.31±1.03 g, and high dose 3.42±1.24 g). Only the highest dose of rhIGF-1 gave statistically significant anabolic effects (P < 0.001 ) and therefore this dose of rhIGF-l (4 mg/kg per d) was chosen for further analysis.
Serum chemistries (Table II) reflected the modest but statistically significant metabolic effects of rhIGF-1. In all three studies there were significant declines in total serum protein, globulin, and cholesterol. Blood urea nitrogen levels fell in two of the studies (B and C). Significant reductions in glucose (study B) and creatinine (study C) occurred less frequently. Thus the effects on lymphoid tissues were observed at doses of rhIGF-l that produced only modest metabolic effects. While serum IGF-1 concentrations were not measured in these studies, serum levels ofthe hormone were examined in subsequent studies. In those experiments, serum IGF-1 concentrations were doubled by 14 d of rhIGF-l treatment. Mice receiving excipient pumps had serum IGF-1 concentrations that averaged 190±23 ng/ml (n = 10) and in the mice receiving rhIGF-1 ( 120 ,gg/d per mouse) serum IGF-l concentrations averaged 392±55 ng/ml (n = 8).
The organ weights ofexcipient-treated mice were very consistent across the studies. There was no significant effect of rhIGF-1 on heart weight in any of the studies. In study B a small, but statistically significant, decrease in liver weight was observed in the IGF-1 treated mice compared to controls ( 1.7
vs. 1.9 g). There was no effect on liver weight after rhIGF-l treatment in the other two studies. The organs that did show the expected increases in weight were the kidney, spleen, and the thymus. The effects of rhIGF-1 on kidney weights were modest, representing 10-15% increases over control values. In contrast, after high-dose rhIGF-1, the spleen weight was greatly increased, nearly doubling compared to controls after 7 d (Fig.  1, top) . No further increase in size occurred after the 14-d treatment. The thymus also showed a large and statistically significant increase in size by day 7 (Fig. 1 b) , which was maintained by 14 d of treatment. Effect of7-d rhIGF-I treatment on lymphocyte subsets. The increased spleen weight after 7 d of 4 mg/kg rhIGF-I was due in large part to an increase in lymphocyte number. Viable lymphocytes, as determined by trypan blue exclusion, increased from 20 x 106 cells/spleen for excipient to 50 X 106 cells/ spleen in the rhIGF-1-treated mice (Fig. 2 a) . When to T cells was changed from 1.9 to 3.0 reflecting a differential increase in the B cell fraction. However, the increase in cell number was due to an increase in both B and T cells. B cell number in the spleen increased threefold (excipient 13 X 106 cells vs. rhIGF-l 35 x 106 cells), whereas the T cell number increased to a lesser (excipient 7 X 106 cells vs. rhIGF-1 11 X 106 cells) but was still statistically significant (P < 0.05) (Fig.  2, c and d) .
The increased thymic weight after rhIGF-1 treatment correlated with a significant increase in the number of Thy 1-positive thymocytes ( 12 X 106 for excipient treated vs. 24 X 106 for rhIGF-1 treated) (Fig. 2 b) . There were no changes in the percentage or mean fluorescent intensity (MFI) in Thy-1, CD4, or CD8 expression on double-positive or single-positive thymocytes as a result of rhIGF-1 treatment. However, there was a consistent and statistically significant (P < 0.05) increase in PNA binding to thymocytes from rhIGF-l-treated mice compared to controls. The data from the 7-d experiment is shown in Fig. 3 . Similar results were observed after 14 d of hormone treatment. In subsequent experiments, peripheral lymph nodes were examined and found to be significantly increased in weight and lymphocyte number (data not shown). Interestingly, the peripheral blood lymphocyte counts decreased from 60/cm3 in the controls to 50/cm3 in the treated mice. Monocyte and eosinophil counts were unchanged. The only statistically significant change in peripheral blood leuko- cytes (P < 0.01 ) was in the neutrophil count which increased from 33% to 48% after rhIGF-1 treatment.
When the subpopulations ofT cells in the spleen were identified in these mice (Fig. 2 c) it was found that CD4+ cells were doubled in number (excipient 4.8 x 106 cells vs. rhIGF-l 9.8 X 1O6 cells). The number of CD8 + cells in the spleen was also significantly increased (from 1.5 x 106 to 2.5 x 106). However, the increase in CD8 + cells was smaller than the increase in the number ofCD4 + cells resulting in an increase in the helper/ suppressor ratio from 3.0 in control mice to 4.1 in the treated mice. However, this increase was not statistically significant.
In contrast to this dramatic increase in lymphocyte number, the mitogenic responses ofsplenic lymphocytes (see Fig. 5 ) from rhIGF-1-treated mice were decreased compared to controls. Both B (LPS) and T cell (Con A) responses were decreased, but only the decline in Con A responsiveness reached statistical significance. The decreased response to PWM, which reflects both T and B cell proliferation, was probably due to effects on the T cell compartment. The stimulation indices reported represent the peak of the proliferative response. The kinetics of the response and concentration of mitogens required for optimal stimulation were identical for both rhIGF-1-treated and control mice.
Effect of 14-d rhIGF-J on lymphocyte subsets. It (Fig. 4, a and b) . Substantial increases in splenic B cell number and modest but significant increases in splenic T cell number were observed (Fig. 4, c and d) . The increase in T cell number once again was due to a large and In contrast to the decreased mitogenic response seen after 7 d of rhIGF-1, the mitogenic response of splenocytes from mice treated for 14 d with rhIGF-1 was significantly elevated compared to controls (Fig. 5) . The SIs for Con A, PWM, and LPS were all increased greater than fourfold by treatment with rhIGF-1. Likewise, the mitogenic response of lymphocytes from the popliteal and mesenteric lymph nodes were also ele- and C (Figs. 2, 4 , 5). The initial differences could be due to many factors including the age or breeding history ofthe mice because they were from retired breeding colonies and as such probably varied between shipments. However, despite these differences, equivalent effects of rhIGF-l were seen in each experiment.
Effect ofrhIGF-I on cell-mediated responses. Experiments were performed to assess the effects of rhIGF-1 on the mixed lymphocyte response. The results in Fig. 6 show that, unlike the stimulatory effects on the T cell mitogenic response, rhIGF-1 failed to enhance the proliferative response to allogeneic splenocytes. Thus antigen-specific T cell responses was unaltered by 14 the possibility that B cell responses to antigenic stimulation might be affected by hormone treatment. As can be seen in Fig.  7 , the baseline level of immunoglobulin production by splenic B cells from the treated mice was twice that ofcontrol lymphocytes. Similarily, when restimulated with exogenous antigen, additional IgG secretion occurred and again the level ofsynthesis was greater in the cultures of splenocytes from 14-d-treated mice compared with controls. Indeed, the level of synthesis in the antigen stimulated cultures of splenocytes from the control mice was equivalent to the baseline level of immunoglobin production of the splenocytes from the rhIGF-1-treated mice. However, in vitro antigen stimulation of splenocytes from rhIGF-1 treatment did not significantly increase IgG synthesis over the baseline level produced by these cells. Because the level of synthesis was so high in the baseline cultures of splenocytes from rhIGF-I-treated mice, this level may reflect the optimal antibody response which can be achieved using these culture conditions. An attempt was made to measure antigenspecific IgG. However, the presence of antigen in the culture supernatants interfered with the ability to measure DNP2OA-specific immunoglobulin using an antigen-specific ELISA.
Discussion IGF-1 was once referred to as a "somatomedin" to indicate that it mediated the whole-body growth-promoting activity of GH (20), but was later named IGF-1 in recognition ofits insulin-like metabolic activities (21) . It is therefore surprising that IGF-1, normally considered to be a metabolic hormone with anabolic and growth-promoting activity, acts as a growth factor for cells of the immune system. Previous studies in mice had centered on the effects of IGF-I on body growth, in particular in Snell dwarf mice. Holder et al. (22) and Van Buul-Offers et al. (23) both reported that IGF-1 could have anabolic activity in these mice when given by subcutaneous injection. In the Little mouse (lit/lit), a strain that is GH-deficient (and therefore IGF-deficient), rhIGF-1 given four times a day (at a total daily dose of 3 mg/kg per d) by subcutaneous injection had anabolic effects (24) . In normal mice we found that when given by subcutaneous infusion similar doses (4 mg/kg per d) of rhIGF-l were necessary to stimulate whole-body growth. Similar doses of rhIGF-1 have been also shown to be necessary to stimulate anabolism in rats where it has become standard practice to infuse rather than to inject rhIGF-1 to produce anabolic effects (see review in reference 25) .
The results reported herein establish that infusions of rhIGF-1 in adult mice produce similar changes in organ growth to those seen with rhIGF-I infusions in GH-deficient rats. For example, there were large growth responses in the kidney, spleen, and thymus, whereas liver and heart did not increase in weight. The 7-and 14-d treatment regimes produced similar increases in weight gains and organ growth. It is therefore unclear whether treatment with rhIGF-l for longer than 14 d would produce a greater and sustained weight gain, as has been shown for GH in adult rats (26) .
We also demonstrate for the first time that the administration of rhIGF-1 to normal mice can produce significant alterations in immune responsiveness. The mice responded to the rhIGF-1 with an increased spleen and thymus weight due to a significant increases in lymphocytes in these organs. An increase in PNA receptor binding, long known to be a marker for immature thymocytes (27) (31, 32) . Treatment of cancer patients with IL-2 does lead to increases in T cell number and cellular immunity (33) . In vivo administration ofIL-1 to mice has been shown to increase total WBC counts, largely granulocytes, and to be beneficial in the treatment of microbial infections (34) . Treatment with endotoxin (35) , a potent B cell mitogen used to induce endogenous cytokine production, has been unsuccessful in increasing B cell numbers in the blood. Whereas endotoxin induced IL-6 and TNF-a, cytokines with lymphocyte growth-promoting activities, only peripheral granulocyte counts increased. rhIGF-1 also failed to increase PBLs, but striking increases in B and T cell numbers occurred in all peripheral lymphoid organs examined. Thus the B cell lymphopoiesis induced by rhIGF-1 is quite unusual.
It is unclear as to which of the well-characterized activities of IGF-1 are mediated in an endocrine, paracrine or autocrine manner. Because IGF-1 can be locally produced by lympho-cytes or stromal cells (28) , it is likely that locally produced IGF-1 may play an autocrine role for these cells. However, it is clear from the results presented herein, that exogenous administration of rhIGF-I has clear effects on lymphoid tissues, which raises the possibility of an endocrine role for IGF-1 on lymphoid tissues. Likewise for GH, a recent report indicates that daily injections of GH results in the reappearance of CD4+/ CD8+ cells within the thymus of DW/J mice which are normally deficient in these double-positive thymocytes (36) . In other experiments we have found that infusions of rhGH induce higher blood IGF-1 concentrations than repeated daily injections of an equivalent amount of rhGH. Further, infusions of either rhIGF-1 or hGH had a much greater effect on lymphoid tissues than daily injections of these hormones. Regardless ofthe mode ofadministration, rhIGF-1 is significantly more potent in inducing alterations in immune parameters than is GH (Clark, et al., manuscript in preparation). It is possible that the effects seen with GH in the DW/J mice are mediated by GH induction of IGF-1.
At present it is difficult to rationalize why the somatogenic hormones GH and IGF-1 should have these major effects on the cells of the immune system. In states of stress, illness, or malnutrition blood IGF-1 concentrations tend to fall in humans (37) , and after an illness it has been reported that the thymus can prematurely involute (38) . The involvement of the endocrine system in this process, particularly of GH and IGF-I remain to be explored. Similar processes may occur in aging where both GH and IGF-1 concentrations decline, in part coincident with a decline in the immune system. The present demonstrations of the ability of rhIGF-1 to regenerate a thymus in an older animal suggests that the involution of the thymus with age might also be affected by GH and IGF-1 status. In nutritional deficiency, which can lead to IGF-1 deficiency, or in aged humans, who are immune compromised compared to younger people, IGF-1 status may be an important factor in the maintenance of immune competence. Because it is known that rhIGF-1 and rhGH are anabolic in several animal models, including those of immune deficiency, we would expect similar anabolic activity in humans in immunedeficient states. In addition to this anabolic activity, we now show evidence in laboratory animals that treatment with rhIGF-1 has positive effects on the immune system. We must await the results of on-going clinical trials with rhIGF-1 to discover whether or not rhIGF-1 will be useful as a therapeutic agent in immune-deficient states in humans.
